From GlobeNewswire: 2025-02-20 08:05:00

IO Biotech is preparing for the launch of Cylembio™, a therapeutic cancer vaccine. The company’s President and CEO will provide an overview at the Cowen Health Care Conference in March 2025. Cylembio™ is currently in Phase 3 trials for advanced melanoma and is being tested in combination with Merck’s KEYTRUDA®. IO Biotech maintains global commercial rights to Cylembio™. The vaccine has shown promising results in clinical trials and has been granted a Breakthrough Therapy Designation by the FDA. For more information, visit the company’s website.



Read more at GlobeNewswire: IO Biotech to Present at the 45th Annual Cowen Health Care